Engineering polysaccharide nanoplatforms for glioblastoma theranostics: Bridging targeted therapy and advanced imaging
Theranostics · 2026
DOI: 10.7150/thno.123550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Theranostics, 2026. Verfasst von Xiaoming Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Institution of Radiology and Medical Imaging, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related…. Hauptthemen laut MEDLINE: Glioblastoma, Theranostic Nanomedicine, Polysaccharides, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive brain tumor characterized by limited therapeutic efficacy and challenges in accurate imaging, largely due to its invasive growth, drug resistance, and the restrictive blood-brain barrier (BBB) hindering the delivery of both therapeutic and diagnostic agents. Current GBM treatments and imaging approaches often suffer from insufficient agent penetration into the tumor. Additionally, they frequently exhibit toxicity or poor signal-to-noise ratios. Polysaccharide (PSC)-based polymers, with their inherent biocompatibility, biodegradability, and versatile chemical modifiability, offer a promising platform to overcome these limitations. These natural polymers can be engineered into sophisticated nanocarriers that enhance BBB traversal, enable targeted tumor accumulation of therapeutic payloads and imaging agents Furthermore, they facilitate controlled drug release and improve diagnostic signal generation. Consequently, PSC-based systems can improve therapeutic efficacy and enhance diagnostic accuracy for tumor visualization. Furthermore, they reduce systemic side effects and support multimodal strategies, ranging from single-modality interventions to integrated theranostic systems. This review aims to comprehensively discuss recent advancements, current challenges, and future perspectives of PSC-based nanomedicines in GBM therapy and imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Institution of Radiology and Medical Imaging, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, National Clinical Research Center for Geriatrics,…
- Psychoradiology Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, and Key Laboratory of Transplant Engineering and Immuno…
- Core Facility of West China Hospital, Sichuan University, Chengdu 610041, China.
- Animal Imaging Core Facilities, West China Hospital, Sichuan University, China.
- Xiamen Key Lab of Psychoradiology and Neuromodulation, Department of Radiology, West China Xiamen Hospital of Sichuan University, Xiamen 361021, China.
Zitieren
APA
Wang, X., Yang, Q., You, S., Wu, L., Gong, Q., & Zeng, Y. (2026). Engineering polysaccharide nanoplatforms for glioblastoma theranostics: Bridging targeted therapy and advanced imaging. Theranostics. https://doi.org/10.7150/thno.123550
Vancouver
Wang X, Yang Q, You S, Wu L, Gong Q, Zeng Y. Engineering polysaccharide nanoplatforms for glioblastoma theranostics: Bridging targeted therapy and advanced imaging. Theranostics. 2026. doi:10.7150/thno.123550
BibTeX
@article{Wang2026,
author = {Wang, Xiaoming and Yang, Qing and You, Shenglan and Wu, Lei and Gong, Qiyong and Zeng, Yujun},
title = {Engineering polysaccharide nanoplatforms for glioblastoma theranostics: Bridging targeted therapy and advanced imaging},
journal = {Theranostics},
year = {2026},
doi = {10.7150/thno.123550}
}
EUVIMED